Abstract
Metoclopramide inhibits the central and peripheral D2 receptors and is frequently prescribed in adults and children as an antiemetic or a prokinetic drug to control symptoms of upper gastrointestinal motor disorders. Metoclopramide is predominantly metabolized via N-dealkylation and it is primarily mediated by CYP2D6 which is highly polymorphic. Thus, the effects of CYP2D6 genetic polymorphism on the pharmacokinetics of metoclopramide were evaluated in this study. All volunteers were genotyped for CYP2D6 and divided into four different genotype groups (CYP2D6*wt/*wt [*wt = *1 or *2], CYP2D6*wt/*10, CYP2D6*10/*10, and CYP2D6*5/*10). Each subject received a single oral dose of metoclopramide 10 mg. Plasma concentrations of metoclopramide were measured by using HPLC-UV. Compared to CYP2D6*wt/*wt, AUCinf of CYP2D6*wt/*10, CYP2D6*10/*10, and CYP2D6*5/*10 significantly increased by 1.5-, 2.3-, and 2.5-fold, respectively. Cmax also increased significantly in comparison to CYP2D6*wt/*wt across all genotype groups, with 1.5-, 1.7-, and 1.7-fold increases seen in CYP2D6*wt/*10, CYP2D6*10/*10, and CYP2D6*5/*10 groups, respectively. The CL/F of metoclopramide decreased in CYP2D6 genotype groups with decreased function alleles, as decreases of 37%, 56% and 61% were observed in CYP2D6*wt/10, *10/10, and *5/*10 genotype groups in comparison to the CYP2D6*wt/*wt group. In conclusion, the genetic polymorphisms of CYP2D6 significantly affected metoclopramide pharmacokinetics.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Explore related subjects
Discover the latest articles and news from researchers in related subjects, suggested using machine learning.References
Byeon JY, Kim YH, Kim SH, Lee CM, Jung EH, Chae WK, Jang CG, Lee SY, Lee YJ (2018a) The influences of CYP2C9*1/*3 genotype on the pharmacokinetics of zolpidem. Arch Pharm Res 41:931–936. https://doi.org/10.1007/s12272-018-1070-y
Byeon JY, Kim YH, Kim SH, Lee CM, Jung EH, Chae WK, Jang CG, Lee SY, Lee YJ (2018b) Effects of genetic polymorphisms of CYP2C19 on the pharmacokinetics of zolpidem. Arch Pharm Res 41:861–866. https://doi.org/10.1007/s12272-018-1065-8
Byeon JY, Kim YH, Lee CM, Kim SH, Chae WK, Jung EH, Choi CI, Jang CG, Lee SY, Bae JW, Lee YJ (2018c) CYP2D6 allele frequencies in Korean population, comparison with East Asian, Caucasian and African populations, and the comparison of metabolic activity of CYP2D6 genotypes. Arch Pharm Res 41:921–930. https://doi.org/10.1007/s12272-018-1075-6
Byeon JY, Lee YJ, Kim YH, Kim SH, Lee CM, Bae JW, Jang CG, Lee SY, Choi CI (2018d) Effects of diltiazem, a moderate inhibitor of CYP3A4, on the pharmacokinetics of tamsulosin in different CYP2D6 genotypes. Arch Pharm Res 41:564–570. https://doi.org/10.1007/s12272-018-1030-6
Byeon JY, Lee CM, Lee YJ, Kim YH, Kim SH, Jung EH, Chae WK, Lee YJ, Jang CG, Lee SY (2019) Influence of CYP2D6 genetic polymorphism on pharmacokinetics of active moiety of tolterodine. Arch Pharm Res 42:182–190. https://doi.org/10.1007/s12272-018-1099-y
Choi CI, Bae JW, Lee YJ, Lee HI, Jang CG, Lee SY (2014) Effects of CYP2C19 genetic polymorphisms on atomoxetine pharmacokinetics. J Clin Psychopharmacol 34:139–142. https://doi.org/10.1097/JCP.0b013e3182a608a2
Chua EW, Harger SP, Kennedy MA (2019) Metoclopramide-induced acute dystonic reactions may be associated with the CYP2D6 poor metabolizer status and pregnancy-related hormonal changes. Front Pharmacol 10:931. https://doi.org/10.3389/fphar.2019.00931
De Oliveira GS Jr, Castro-Alves LJ, Chang R, Yaghmour E, McCarthy RJ (2012) Systemic metoclopramide to prevent postoperative nausea and vomiting: a meta-analysis without Fujii’s studies. Br J Anaesth 109:688–697. https://doi.org/10.1093/bja/aes325
Derry S, Moore RA (2013) Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev 30:008040. https://doi.org/10.1002/14651858.CD008040.pub3
Desta Z, Wu GM, Morocho AM, Flockhart DA (2002) The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6. Drug Metab Dispos 30:336–343. https://doi.org/10.1124/dmd.30.3.336
El-Sayed YM, Niazy EM, al-Rayes S, Ismail AO, Gouda MW (1995) Comparative bioavailability of two tablet formulations of metoclopramide hydrochloride. Int J Clin Pharmacol Ther 33:136–139
Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Klein T, Leeder JS (2017) Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med 19:69–76. https://doi.org/10.1038/gim.2016.80
Harrington RA, Hamilton CW, Brogden RN, Linkewich JA, Romankiewicz JA, Heel RC (1983) Metoclopramide. An updated review of its pharmacological properties and clinical use. Drugs 25:451–494. https://doi.org/10.2165/00003495-198325050-00002
Ingelman-Sundberg M (2005) Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5:6–13. https://doi.org/10.1038/sj.tpj.6500285
Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C (2007) Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496–526. https://doi.org/10.1016/j.pharmthera.2007.09.004
Ingelman-Sundberg M, Daly AK, Nebert DW (2020) Homepage of the human cytochrome P450 (CYP) allele nomenclature database: CYP2D6 allele nomenclature, https://www.pharmvar.org/htdocs/archive/cyp2d6.htm. Accessed 22 Dec 2020
Kemp CA, Flanagan JU, van Eldik AJ, Maréchal JD, Wolf CR, Roberts GC, Paine MJ, Sutcliffe MJ (2004) Validation of model of cytochrome P4502D6: an in silico tool for predicting metabolism and inhibition. J Med Chem 47:5340–5346. https://doi.org/10.1021/jm049934e
Kim SH, Kim DH, Byeon JY, Kim YH, Kim DH, Lim HJ, Lee CM, Whang SS, Choi CI, Bae JW, Lee YJ, Jang CG, Lee SY (2017) Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metabolite. Arch Pharm Res 40:382–390. https://doi.org/10.1007/s12272-016-0861-2
Kim MJ, Byeon JY, Kim YH, Kim SH, Lee CM, Jung EH, Chae WK, Lee YJ, Jang CG, Lee SY, Choi CI (2018a) Effect of the CYP2D6*10 allele on the pharmacokinetics of clomiphene and its active metabolites. Arch Pharm Res 41:347–353. https://doi.org/10.1007/s12272-018-1005-7
Kim SH, Byeon JY, Kim YH, Lee CM, Lee YJ, Jang CG, Lee SY (2018b) Physiologically based pharmacokinetic modelling of atomoxetine with regard to CYP2D6 genotypes. Sci Rep 8:12405. https://doi.org/10.1038/s41598-018-30841-8
Lee HI, Bae JW, Choi CI, Lee YJ, Byeon JY, Jang CG, Lee SY (2014) Strongly increased exposure of meloxicam in CYP2C9*3/*3 individuals. Pharmacogenet Genom 24:113–117. https://doi.org/10.1097/FPC.0000000000000025
Lee HJ, Kim YH, Kim SH, Lee CM, Yang AY, Jang CG, Lee SY, Bae JW, Choi CI (2016) Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of zafirlukast. Arch Pharm Res 39:1013–1019. https://doi.org/10.1007/s12272-016-0785-x
Lee HI, Byeon JY, Kim YH, Lee CM, Choi CI, Jang CG, Bae JW, Lee YJ, Lee SY (2018) Effects of CYP2C19 and CYP3A5 genetic polymorphisms on the pharmacokinetics of cilostazol and its active metabolites. Eur J Clin Pharmacol 74:1417–1426. https://doi.org/10.1007/s00228-018-2522-5
Leucuţa A, Vlase L, Farcău D, Nanulescu M (2004) Pharmacokinetic interaction study between ranitidine and metoclopramide. Rom J Gastroenterol 13(3):211–214
Livezey MR, Briggs ED, Bolles AK, Nagy LD, Fujiwara R, Furge LL (2014) Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6. Xenobiotica 44:309–319. https://doi.org/10.3109/00498254.2013.835885
Masiongale AJ, Garvin JT, Murphy MJ, Hooper VD, Odom-Forren J, Masiongale JI, Looney SW (2018) Reexamining metoclopramide’s role in the prevention of postoperative nausea and vomiting: a secondary analysis. AANA J 86:213–219
McParlin C, O’Donnell A, Robson SC, Beyer F, Moloney E, Bryant A, Bradley J, Muirhead CR, Nelson-Piercy C, Newbury-Birch D, Norman J, Shaw C, Simpson E, Swallow B, Yates L, Vale L (2016) Treatments for hyperemesis gravidarum and nausea and vomiting in pregnancy: a systematic review. JAMA 316:1392–1401. https://doi.org/10.1001/jama.2016.14337
Orme ML, Tallis RC (1984) Metoclopramide and tardive dyskinesia in the elderly. Br Med J 289:397–398. https://doi.org/10.1136/bmj.289.6442.397
Parkman HP, Mishra A, Jacobs M, Pathikonda M, Sachdeva P, Gaughan J, Krynetskiy E (2012) Clinical response and side effects of metoclopramide: associations with clinical, demographic, and pharmacogenetic parameters. J Clin Gastroenterol 46:494–503. https://doi.org/10.1097/MCG.0b013e3182522624
Rao AS, Camilleri M (2010) Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther 31:11–19. https://doi.org/10.1111/j.1365-2036.2009.04189.x
Shakhatreh M, Jehangir A, Malik Z, Parkman HP (2019) Metoclopramide for the treatment of diabetic gastroparesis. Expert Rev Gastroenterol Hepatol 13:711–721. https://doi.org/10.1080/17474124.2019.1645594
Stosik AG, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM (2008) Biowaiver monographs for immediate release solid oral dosage forms: metoclopramide hydrochloride. J Pharm Sci 97:3700–3708. https://doi.org/10.1002/jps.21276
Teh LK, Bertilsson L (2012) Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance. Drug Metab Pharmacokinet 27:55–67. https://doi.org/10.2133/dmpk.dmpk-11-rv-121
Tonini M, Cipollina L, Poluzzi E, Crema F, Corazza GR, De Ponti F (2004) Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment Pharmacol Ther 19:379–390. https://doi.org/10.1111/j.1365-2036.2004.01867.x
van der Padt A, van Schaik RHN, Sonneveld P (2006) Acute dystonic reaction to metoclopramide in patients carrying homozygous cytochrome P450 2D6 genetic polymorphisms. Neth J Med 64:160–162
Vlase L, Leucuta A, Farcau D, Nanulescu M (2006) Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers. Biopharm Drug Dispos 27:285–289. https://doi.org/10.1002/bdd.510
Acknowledgements
This research was supported the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT, & Future Planning (NRF-2019R1A2C1004582).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Bae, JW., Oh, KY., Yoon, SJ. et al. Effects of CYP2D6 genetic polymorphism on the pharmacokinetics of metoclopramide. Arch. Pharm. Res. 43, 1207–1213 (2020). https://doi.org/10.1007/s12272-020-01293-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-020-01293-4